Phaseline

Targets › ESRRG

ESRRG (Estrogen-related receptor gamma): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology.

Orphan receptor that acts as a transcription activator in the absence of bound ligand. Binds specifically to an estrogen response element and activates reporter genes controlled by estrogen response elements (By similarity). (UniProt, P62508)

Open in Phaseline: the race on ESRRG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Northwestern UniversityAfimoxifene
Estrogen receptor modulator; Estrogen-related receptor gamma antagonist
ESR2, ESR1, ESRRGPhase 2Cancer Survivor–

Conditions

Cancer Survivor (1)

Modalities

small molecule (1)

Companies

Northwestern University (1)

Related targets

ESR2 (1) ESR1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.